Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular and Renal Outcomes: A Meta-Analysis and Meta-Regression Analysis

Satoshi Yoshiji[1–4], Hiroto Minamino[1,4], Daisuke Tanaka[1], Shunsuke Yamane[1], Norio Harada[1], and Nobuya Inagaki[1]

[1]Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan

[2]Department of Human Genetics, McGill University, Montréal, Québec, Canada

[3]Kyoto-McGill International Collaborative Program in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

[4]Japan Society for the Promotion of Science, Tokyo, Japan

Correspondence

Nobuya Inagaki

Professor and Chairman,

Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

E-mail: inagaki@kuhp.kyoto-u.ac.jp

Tel: +81-075-751-3560

Fax: +81-075-751-4244

Word Counts:

Abstract (including subheadings): 248

Main body of the text (excluding references and legends): 3152 (including headings)

Number of references: 41

Number of Tables and Figures: 1 table and 4 figures

Abstract

Aims: Cardiovascular and renal effects of glucagon-like peptide-1 receptor agonists (GLP-

1RAs) have been inconsistent in cardiovascular outcome trials, and factors associated with the

efficacy of GLP-1RAs remain to be clarified. Here, we evaluate the cardiovascular and renal

outcomes with GLP-1RAs and associations between these outcomes and HbA1c or weight

reduction.

Materials and Methods: We searched PubMed/MEDLINE, EMBASE, and CENTRAL for

randomized, placebo-controlled trials of GLP1-RAs reporting major adverse cardiovascular

events (MACE; a composite of cardiovascular mortality, stroke, and myocardial infarction) as

the primary outcome. We conducted a meta-regression analysis of primary and secondary

outcomes with HbA1c or weight reduction following a meta-analysis with a random-effects

model for these outcomes.

Results: We extracted data of 60,800 individuals from eight eligible studies (ELIXA, LEADER,

SUSTAIN-6, EXSCEL, HARMONY, PIONEER 6, REWIND, and AMPLITUDE-O). GLP-

1RAs reduced MACE (hazard ratio [HR] 0.86; 95% CI: 0.80–0.93; $P < 0.001$) and secondary

outcomes including the composite renal outcome (0.80; 0.73–0.87; $P < 0.001$). In meta-

regression analysis, every 1% reduction in HbA1c was associated with 26% and 35% decreases

in the logarithm of HR of MACE ($P = 0.044$; $R^2 = 0.65$) and the composite renal outcome ($P =$

0.040; $R^2 = 0.85$), respectively. On the contrary, weight reduction was not associated with any

outcome, including MACE ($P = 0.390$).

Conclusions: The reduction in HbA1c, but not body weight, is associated with cardiovascular

and renal outcomes. The magnitude of HbA1c reduction can be a surrogate for cardiovascular

and renal benefits of treatment with GLP-1RAs.

Introduction

Major adverse cardiovascular events (MACE) and chronic kidney diseases are leading causes of

morbidity and mortality in individuals with type 2 diabetes. Glucagon-like peptide-1 receptor

agonists (GLP-1RAs) have shown cardiovascular and renal benefits in cardiovascular outcome

trials and played a key role in the management of type 2 diabetes.[1, 2]

To date, a series of randomized, placebo-controlled clinical trials on cardiovascular and

renal outcomes with GLP-1RAs has been reported, including ELIXA with lixisenatide,

LEADER with liraglutide, SUSTAIN-6 with semaglutide, EXSCEL with exenatide once weekly,

HARMONY with albiglutide, PIONEER 6 with oral semaglutide, REWIND with dulaglutide,

and AMPLITUDE-O with efpeglenatide.[3-10] These trials evaluated the safety and efficacy of

GLP-1RAs regarding the primary composite MACE outcome (cardiovascular mortality, stroke,

or myocardial infarction), components of MACE, hospitalization due to heart failure, all-cause

mortality, and renal outcomes. GLP-1RAs consistently showed cardiovascular and renal safety,

but the cardiovascular and renal efficacies were inconsistent across the trials. Thus, further

studies are warranted to elucidate factors associated with cardiovascular and renal benefits of

GLP-1RAs.

Regarding the mechanism of action for cardiovascular and renal efficacies, it has been

reported that reducing HbA1c or body weight contributes to cardiovascular, renal, and mortality

risk reduction in legacy studies.[11-16] However, although cardiovascular outcome trials of GLP-

1RAs have reported an effective reduction in HbA1c and body weight, it remains unclear

whether HbA1c or body weight reduction is associated with the cardioprotective and

renoprotective profiles.

To examine the overall cardiovascular and renal efficacies of GLP-1RAs, we performed a

meta-analysis of cardiovascular outcome trials of GLP-1RAs. We then conducted a meta-

regression analysis to evaluate whether the reduction in HbA1c or body weight is associated with

cardiovascular and renal efficacies of GLP-1RAs.

Methods

Data Sources and Search

We performed a data search in accordance with the Preferred Reporting Items for Systematic

Reviews and Meta-Analysis (PRISMA) statement.[17] We searched the PubMed/MEDLINE,

EMBASE, and CENTRAL databases for eligible randomized, placebo-controlled trials of GLP-

1RAs reporting MACE in individuals with type 2 diabetes, published until January 23, 2022. We

placed no restrictions on the study population or language. The following search terms were

used: "glucagon-like peptide-1 receptor agonist," "GLP-1 receptor agonist," "lixisenatide,"

"liraglutide," "semaglutide," "exenatide," "albiglutide," "liraglutide," "oral semaglutide,"

"efpeglenatide," "type 2 diabetes," "randomized controlled trial," "randomized placebo-

controlled trial," "Major adverse cardiovascular events," "MACE," "cardiovascular mortality,"

"myocardial infarction," "acute coronary syndrome," "cardiovascular," "stroke," "death," "heart

failure," "kidney disease," and "renal." The PRISMA flow diagram is presented in **Figure 1**. The

protocol for this study is registered in PROSPERO (CRD42021273058).

Study Selection

We selected studies reporting MACE as the primary outcome.

Data Extraction and Quality Assessment

We extracted summary statistics of the eligible studies from published articles of the trials and

their supplementary materials. We did not seek individual-level data. For the primary and

secondary outcomes, we obtained relevant hazard ratio (HR) and 95% confidence interval (95%

CI) data. We evaluated the risk of bias for eligible studies with the Cochrane Risk of Bias Tool.[18]

SY and HM conducted data extraction and quality assessment. SY and HM independently

conducted the search and solved any discordance through discussion.

Data Synthesis and Analysis

The primary outcome was the HR of MACE. The secondary outcomes were the HR of individual

components of MACE, all-cause mortality, hospitalization due to heart failure, composite renal

outcome, and renal function outcome. The definitions of "composite renal outcome" and "renal

function outcome" were not standardized across the trials; detailed definitions of these renal

outcomes in each trial are provided in **Supplementary Table 1**.

For the meta-analysis, we used the inverse variance method with a random-effects

model to obtain a weighted average of HR with 95% CI for each outcome. We used

the DerSimonian-Laird estimator for the assessment of between-study variance.[19] We used the I^2

index and Cochran's Q test to measure the degree of heterogeneity. The degree of heterogeneity

based on the I^2 index was defined as low (I^2 index $\leq 25\%$), moderate (I^2 index 26–50%), and

high (I^2 index $> 50\%$).[20] Results with $P < 0.05$ in Cochran's Q test represent significant

heterogeneity between the studies.

Regarding meta-regression analysis, normalized HbA1c and body weight reduction by

each GLP-1RA were calculated from head-to-head clinical trials as described previously.[21] For

normalization, we defined HbA1c reduction and body weight reduction of liraglutide as 1.0%

and 1.0 kg, respectively, considering that liraglutide was compared head-to-head against all the

other GLP-1RAs.[22–28] Using the following equations (1) and (2), we normalized the HbA1c and

body weight reduction of each GLP-1RA against those of liraglutide by taking the ratio of

their %HbA1c reduction and %body weight reduction from baseline, respectively

(**Supplementary Table 3**):

$$\text{Normalized HbA1c reduction (\%)} = 1.0 \times \frac{\text{\%HbA1c reduction from baseline of each GLP-1RA}}{\text{\%HbA1c reduction from baseline of liraglutide}}$$

$$\text{Normalized body weight reduction (kg)} = 1.0 \times \frac{\text{\%body weight reduction from baseline of each GLP-1RA}}{\text{\%body weight reduction from baseline of liraglutide}}$$

Using either normalized HbA1c change or body weight change as an independent

variable, we conducted univariable meta-regression analyses with a mixed-effects model for

cardiovascular and renal outcomes with the logarithm of HR (log-HR) as a dependent variable.

Results with $P < 0.05$ were considered significant.

We performed all statistical analyses with R (version 4.0.2), using the R packages meta

(version 4.18.2) and metafor (version 3.02).

Results

Study identification

Among the 225 articles screened with the prespecified screening strategy, eight randomized,

placebo-controlled cardiovascular outcome trials reporting MACE as the primary outcome were

identified. Data from the following eight trials involving 60,080 individuals were analyzed in the

present meta-analysis: ELIXA with lixisenatide, LEADER with liraglutide, SUSTAIN-6 with

semaglutide, EXSCEL with exenatide once weekly, HARMONY with albiglutide, PIONEER 6

with oral semaglutide, REWIND with dulaglutide, and AMPLITUDE-O with efpeglenatide. The

study selection process based on PRISMA is presented in **Figure 1**. According to the Cochrane

risk of bias tool,[18] the risk of bias for all included trials was evaluated as low (**Supplementary**

Table 2).

For all trials except for ELIXA, the primary outcome was MACE, which was the time to

the first occurrence of cardiovascular mortality, stroke, or myocardial infarction. For ELIXA, the

primary outcome was extended MACE, which was MACE with an additional component, i.e.,

hospitalization due to unstable angina. However, hospitalization due to unstable angina

accounted for less than 2.5% of the primary outcome in ELIXA. Considering that hospitalization

for unstable angina had a minimal influence on the primary outcome, we included ELIXA in the

meta-analysis and meta-regression analysis. HARMONY and PIONEER 6 did not report renal

outcomes and were excluded from the analysis of renal outcomes.

Baseline characteristics

The baseline characteristics and other details of the eight trials are summarized in **Table 1**. The

median duration of follow-up was the shortest in PIONEER 6 (1.3 years) and the longest in

REWIND (5.4 years). The average age of patients ranged from 59.9 years in ELIXA to 66.2

years in REWIND. Of the 60,080 individuals, 21,930 (37%) were women, and 45,640 (76%)

were of white ethnicity. The average body mass index varied from 30.1 kg/m^2 (ELIXA) to 32.8

kg/m^2 (SUSTAIN-6), average baseline HbA1c ranged from 7.3% (REWIND) to 8.9%

(AMPLITUDE-O), and average estimated glomerular filtration rate (eGFR) from 74 mL/min per

1.73 m^2 (PIONEER 6) to 80 mL/min per 1.73 m^2 (LEADER and SUSTAIN-6). The proportion

of individuals with previously established cardiovascular disease was 77% (46,105 out of 60,080

individuals) across the eight trials and ranged from 31% (REWIND) to 100% (ELIXA and

HARMONY).

Meta-analysis

Overall, GLP-1RAs reduced MACE (HR: 0.86; 95% CI: 0.80–0.93; $P < 0.001$; $I^2 = 44.5\%$)

(**Figure 2**). As for the individual components of MACE, GLP-1RAs reduced cardiovascular

mortality (HR: 0.87; 95% CI: 0.80–0.94; $P = 0.001$; $I^2 = 12.8\%$), myocardial infarction (HR:

0.90; 95% CI: 0.83–0.98; $P = 0.020$; $I^2 = 27.4\%$), and stroke (HR: 0.83; 95% CI: 0.76–0.92; $P <$

0.001; $I^2 = 0\%$).

148   As for the other secondary outcomes, GLP-1RAs reduced composite renal outcome

(HR: 0.80; 95% CI: 0.73–0.87; $P < 0.001$; $I^2 = 45.0\%$) (**Figure 2**), all-cause mortality (HR: 0.88;

95% CI: 0.82–0.94; $P < 0.001$; $I^2 = 10.5\%$), hospitalization due to heart failure (HR: 0.89; 95%

CI: 0.82–0.98; $P = 0.013$; $I^2 = 2.5\%$), and renal function outcome (HR: 0.84; 95% CI: 0.73–0.97;

$P = 0.016$; $I^2 = 31.4\%$) (**Supplementary Figure 1**).

Subgroup analysis

In a subgroup analysis of MACE stratified by the structural backbones of GLP-1RAs

(**Supplementary Figure 2**), exendin-based GLP-1RAs did not reduce MACE with high

heterogeneity (HR: 0.90; 95% CI: 0.78–1.04; $P = 0.163$; $I^2 = 67.2\%$). On the contrary, human

GLP-1-based GLP-1RAs reduced MACE with low heterogeneity (HR: 0.84; 95% CI: 0.79–0.90;

$P < 0.001$).

160   In another subgroup analysis of MACE stratified by the history of established

cardiovascular disease (**Supplementary Figure 3**), GLP-1RAs reduced MACE in individuals

with established cardiovascular disease (HR: 0.85; 95% CI: 0.79–0.92; $P < 0.001$; $I^2 = 48.0\%$)

but not in those without established cardiovascular disease (HR: 0.94; 95% CI: 0.83–1.06; $P =$

0.303; $I^2 = 0.0\%$).

Meta-regression analysis

Normalized HbA1c and body weight reduction used in the meta-regression analysis are

presented in **Supplementary Table 3**. The meta-regression analysis of the eight pooled trials

showed that normalized HbA1c reduction was associated with the log-HR of MACE (slope: –

0.26; 95% CI: –0.52 to –0.01; $P = 0.044$; $R^2 = 0.65$); i.e., every 1% reduction in HbA1c was

associated with a 26% decrease in log-HR of MACE ($P = 0.044$). On the contrary, normalized

body weight reduction showed no association with the log-HR of MACE (slope: –0.05; 95% CI:

–0.17 to 0.07; $P = 0.390$; $R^2 < 0.01$) (**Figure 3**). Among the secondary outcomes, normalized

HbA1c reduction was associated with the log-HR of the composite renal outcome (slope: –0.35;

95% CI: –0.68 to –0.02; $P = 0.040$; $R^2 = 0.85$) (**Figure 4**), which means that every 1% reduction

in HbA1c was associated with 35% decrease in the logarithm of HR (log-HR) of MACE.

Although the associations between normalized HbA1c reduction and other secondary outcomes

were not significant, all outcomes except hospitalization due to heart failure showed negative

slopes for the regression line, which was directionally concordant with MACE. As for body

weight, normalized body weight reduction was not associated with any secondary outcome; the

95% CIs were wide and ranged from negative to positive values (**Figure 4** and **Supplementary**

Figure 4).

Discussion

The present meta-analysis and meta-regression analysis involved 60,080 individuals from eight

cardiovascular outcome trials, including the latest evidence from AMPLITUDE-O. In the meta-

analysis, GLP-1RAs reduced MACE, its components, cardiovascular mortality, myocardial

infarction, stroke, all-cause mortality, hospitalization due to heart failure, the composite renal

outcome, and the renal function outcome. In meta-regression analysis, a reduction in HbA1c was

associated with a decrease in log-HR of MACE and the composite renal outcome. On the

contrary, weight reduction was not associated with any outcome. To the best of our knowledge,

this is the largest study combining meta-analysis and meta-regression analysis to evaluate

cardiovascular and renal efficacies of GLP-1RAs.

Our meta-analysis reaffirms the cardiovascular and renal benefits of GLP-1RAs

suggested by previous studies[29–31] and supports the current guidelines that recommend GLP-

1RAs for the treatment of diabetes in individuals with established cardiovascular diseases or in

those who are at high risk of cardiovascular diseases.[1, 2, 32, 33] In addition to the trials included in

previous meta-analyses, our study also included AMPLITUDE-O, which is the latest trial using

the GLP-1RA with the exendin backbone to show the successful reduction of MACE. By

including AMPLITUDE-O, our meta-analysis increased the sample size by 4,076, providing

more robust evidence on GLP-1RA efficacy.

In a subgroup analysis stratified by the history of established cardiovascular disease

(Supplementary Figure 2), GLP-1RAs reduced MACE in individuals with established

cardiovascular disease but not in those without established cardiovascular disease. Taking into

account the anti-atherosclerotic properties of GLP-1RAs,[34] it is conceivable that the

cardiovascular benefits of GLP-1RAs were more prominent in individuals with established

cardiovascular disease.

In terms of individual study details, all studies, except for ELIXA and EXSCEL,

reported a reduction in MACE. Notably, in AMPLITUDE-O, efpeglenatide reduced MACE for

the first time as an exendin-based GLP-1RA. Based on the findings from AMPLITUDE-O, we

conducted the subgroup analysis of MACE according to the structural backbone of GLP-1RAs

(Supplementary Figure 3). While human GLP-1-based GLP-1RAs reduced MACE (HR: 0.84;

95% CI: 0.79–0.90; $P < 0.001$) with low heterogeneity ($I^2 = 0.0\%$, $P = 0.513$), exendin-based

GLP-1RAs did not reduce MACE (HR: 0.90; 95% CI: 0.78–1.04; $P = 0.163$). The difference

could be due to the large heterogeneity of exendin-based GLP-1 trials ($I^2 = 67.2\%$, $P = 0.047$).

Individually, ELIXA was different from the other two trials (EXSCEL and AMPLITUDE-O) in

terms of recruited individuals with a recent acute coronary syndrome.[3] It should also be noted

that EXSCEL reported poor adherence to the drug (around 40% of premature discontinuation of

the trial) and that lixisenatide, used in ELIXA, has a half-life of 2–4 h, which is considerably

shorter than that of other GLP-1RAs.[35] Therefore, in ELIXA and EXSCEL, multiple factors such

as study design, adherence to the drug, and half-life could have influenced the cardiovascular

outcomes. On the contrary, in AMPLITUDE-O, a reduction in MACE and other secondary

outcomes was achieved despite the shortest follow-up period of 1.8 years (2.1 years for ELIXA

and 3.2 years for EXSCEL),[3, 6, 10] showing that exendin-based GLP-1RAs can also exert

cardioprotective and renoprotective effects.

Regarding the underlying mechanism of GLP-1RA efficacy, factors associated with the

cardioprotective and renoprotective profiles of GLP-1RAs remained to be clarified.[36] Therefore,

to determine whether the reduction in HbA1c or body weight (two key clinical variables

decreased by GLP-1RAs) is associated with the cardioprotective and renoprotective effects of

GLP-1RAs, we conducted a meta-regression analysis of the log-HR of MACE and other

secondary outcomes with normalized reduction in HbA1c or body weight.

As for the primary composite MACE outcome (**Figure 3**), the results showed that the

log-HR of MACE decreased by 26% for every 1.0% normalized HbA1c reduction. In contrast,

log-HR of MACE was not associated with normalized body weight reduction. In individual

studies, albiglutide caused minimal weight reduction but still showed a reduction in log-HR of

MACE. Contrarily, lixisenatide, which showed a greater normalized body weight reduction than

albiglutide and dulaglutide, did not reduce cardiovascular risk.

The present finding that only HbA1c reduction, but not body weight reduction, is

associated with cardiovascular risk is consistent with that of a recent post-hoc mediation study of

the LEADER trial.[37] The mediation analysis showed that HbA1c was potentially the largest

mediator of cardiovascular efficacy of liraglutide, with percentage mediation being 41–83%,

whereas body weight was calculated to have a considerably lower percentage mediation of 4–

14%. Considering the findings of our meta-regression analysis and the mediation analysis, it

seems likely that HbA1c reduction can be a marker of cardiovascular efficacy of GLP-1RAs.

However, whether HbA1c reduction constitutes a direct contributor or represents unmeasured

contributors remains to be clarified. In addition to glucose-lowering effects, pleiotropic effects,

including amelioration of endothelial damage and chronic inflammation,[38, 39] are potential

contributors to cardiovascular risk reduction with GLP-1RAs.

As for the secondary outcomes, every 1.0% normalized HbA1c reduction was

associated with a 35% decrease in log-HR of the composite renal outcome. On the contrary,

normalized body weight reduction presented a high variability among studies and was not

associated with any secondary outcome (**Figure 4** and **Supplementary Figure 2**). Consistent

with our finding that the reduction in HbA1c, but not body weight, is associated with the

composite renal outcome, another mediation analysis of the LEADER and SUSTAIN 6 trials on

the composite renal outcome suggested that HbA1c is potentially the greatest mediator of renal

benefits, whereas body weight has little to no effect.[39] In contrast to the association of HbA1c

reduction with the renal composite outcome, we did not find a significant association with the

renal function outcome (the narrower renal endpoint). This discrepancy may be explained by the

definitions of these outcomes: the renal composite outcome included new-onset

macroalbuminuria, which is predominantly prevented by GLP-1RAs,[40] whereas the renal

function outcome did not (**Supplementary Table 1**). However, we must note that cardiovascular

outcome trials were not designed to detect renal events as the primary outcome. In this regard,

the ongoing FLOW trial (NCT03819153),[41] which evaluates the effects of semaglutide on hard

renal endpoints as the primary outcome in individuals with chronic kidney disease, is expected to

provide more insights into the renal effects of the GLP-1RAs.

This study has some limitations. First, we used only summary data for meta-analysis

and did not use individual-level data. Second, although heterogeneity between studies was

generally low for most of the outcomes, moderate heterogeneity was observed for the renal

composite outcome and the renal function. This is likely because definitions of renal outcomes

were not standardized across the trials (**Supplementary Table 1**). Third, although we conducted

the meta-analysis and meta-regression analyses on various secondary outcomes in addition to the

primary outcome, the included trials were not sufficiently powered to detect the differences in

the secondary outcomes. This may have reduced the statistical power for meta-regression

analysis of the secondary outcomes.

In conclusion, GLP-1RAs reduce MACE, its components, all-cause mortality,

hospitalization due to heart failure, the composite renal outcome, and the renal function outcome.

The meta-regression analysis showed that the reduction in HbA1c, but not body weight, is

associated with cardiovascular and renal outcomes of GLP-1RAs. The magnitude of HbA1c

reduction can be a surrogate for cardiovascular and renal benefits of treatment with GLP-1RAs.

References

1.   Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of hyperglycemia in

type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the

European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2020;43:487-493.

2.   Andreasen CR, Andersen A, Knop FK, Vilsboll T. Understanding the place for GLP-1RA

therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice

and patient selection. *Diabetes Obes Metab* 2021; 23 Suppl 3: 40-52.

3.   Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and

acute coronary syndrome. *New Engl J Med.* 2015;373:2247-2257.

4.   Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular

outcomes in type 2 diabetes. *New Engl J Med.* 2016;375:311-322.

5.   Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in

patients with type 2 diabetes. *New Engl J Med.* 2016;375:1834-1844.

6.   Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on

cardiovascular outcomes in type 2 diabetes. *New Engl J Med.* 2017;377:1228-1239.

7.   Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes

in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind,

randomised placebo-controlled trial. *Lancet.* 2018;392:1519-1529.

8.   Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular

outcomes in patients with type 2 diabetes. *New Engl J Med.* 2019;381:841-851.

9.   Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes

in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet.*

2019;394:121-130.

10.   Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with

efpeglenatide in type 2 diabetes. *New Engl J Med.* 2021;385:896-907.

11.   Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the

development and progression of long-term complications in insulin-dependent diabetes mellitus.

New Engl J Med. 1993;329:977-986.

12.   Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and

cardiovascular disease in patients with type 1 diabetes. *New Engl J Med.* 2005;353:2643-2653.

13.   UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared

with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS

33). *Lancet.* 1998;352:837-853.

14.   UKPDS Group. Effect of intensive blood-glucose control with metformin on

complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet.* 1998; 352:854-

865.

15.   Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in

type 2 diabetes. *New Engl J Med.* 2008;359:1577-1589.

16.   Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for adults who are

obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis.

BMJ. 2017;359:j4849.

17.   Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated

guideline for reporting systematic reviews. *BMJ.* 2021;327:n71.

18.   Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane collaboration's tool for

assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928-d.

19.   DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. *Contemp Clin Trials*.

2015;45:139-145.

20.   Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing

heterogeneity in meta-analysis: Q statistic or I^2 index? *Psychol Methods.* 2006;11:193-206.

21.   Taylor SI. GLP-1 receptor agonists: differentiation within the class. *Lancet Diabetes*

Endocrinol. 2018;6:83-85.

22.   Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in

patients with type 2 diabetes (DURATION-6): a randomised, open-label study. *Lancet.*

2013;381:117-124.

23.   Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily

liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-

label, phase 3, non-inferiority trial. *Lancet.* 2014;384:1349-1357.

24.   Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily

liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY

7): a randomised, open-label, multicentre, non-inferiority phase 3 study. *Lancet Diabetes*

Endocrinol. 2014;2:289-297.

25.   Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B. Once-daily

liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: A 26-week randomized

controlled clinical trial. *Diabetes Care.* 2016;39:1501-1509.

26.   Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and

placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. *Lancet.*

2019;394:39-50.

27.   Rosenstock J, Sorli CH, Trautmann ME, et al. Once-weekly efpeglenatide dose-range

effects on glycemic control and body weight in patients with type 2 diabetes on metformin or

drug naive, referenced to liraglutide. *Diabetes Care.* 2019;42:1733-1741.

28.   Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly

semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in

subjects with type 2 diabetes (SUSTAIN 10). *Diabetes Metab.* 2020; 46:100-109.

29   Pantalone KM, Munir K, Hasenour CM, et al. Cardiovascular outcomes trials with

glucagon□like peptide□1 receptor agonists: A comparison of study designs, populations and

results. *Diabetes Obes Metab* 2020;22:2209-2226.

30.   Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes

with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-

analysis of cardiovascular outcome trials. *Lancet Diabetes Endocrinol* 2019; 7: 776-785.

31   Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-

2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes:

systematic review and network meta-analysis of randomised controlled trials. *BMJ* 2021; 372:

m4573.

32.   Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision pathway on

novel therapies for cardiovascular risk reduction in patients with type 2 Diabetes. *J Am Coll*

Cardiol. 2020;76:1117-1145.

33.   American Diabetes Association. Cardiovascular disease and risk management: standards

of medical care in diabetes—2021. *Diabetes Care.* 2021;44:S125-S150.

34.   Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. *Cell Metab.*

2016;24:15-30.

35.   Aroda VR. A review of GLP-1 receptor agonists: Evolution and advancement, through

the lens of randomised controlled trials. *Diabetes Obes Metab* 2018; 20: 22-33.

36.   Caruso I, Cignarelli A, Giorgino F. Heterogeneity and similarities in GLP-1 receptor

agonist cardiovascular outcomes trials. *Trends Endocrinol Metab.* 2019;30:578-589.

37.   Buse JB, Bain SC, Mann JFE, et al. Cardiovascular risk reduction with liraglutide: An

exploratory mediation analysis of the LEADER Trial. *Diabetes Care.* 2020;43:1546-1552.

38.   Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic effects of GLP-1 and analogs

on cell signaling, metabolism, and function. *Front Endocrinol (Lausanne).* 2018; 9: 672.

39.   Mann JFE, Buse JB, Idorn T, et al. Potential kidney protection with liraglutide and

semaglutide: Exploratory mediation analysis. *Diabetes Obes Metab.* 2021;23:2058-2066.

40.   Vitale M, Haxhi J, Cirrito T, Pugliese G. Renal protection with glucagon-like peptide-1

receptor agonists. *Curr Opin Pharmacol.* 2020;54:91-101.

41.   Novo Nordisk. A Research study to see how semaglutide works compared to placebo in

people with type 2 diabetes and chronic kidney disease. Identifier: NCT03819153.

https://clinicaltrials.gov/ct2/show/NCT03819153. Accessed 23 January 2022.

Legends to figures

Figure 1. PRISMA flow diagram for identification of studies.

Figure 2. Effects of GLP-1RAs on three-point MACE outcome, cardiovascular mortality,

myocardial infarction, stroke, and composite renal outcome.

MACE = major adverse cardiovascular events.

Figure 3. Univariable meta-regression analysis of normalized reduction in HbA1c (A) or body

weight (B) with the logarithm of hazard ratio (log-HR) for the primary composite MACE

outcome.

The size of each trial's circle is inversely proportional to the variance of hazard ratio.

MACE = major adverse cardiovascular events.

Figure 4. Univariable meta-regression analysis of normalized reduction in HbA1c reduction (A–

D) or body weight (E–H) with the logarithm of hazard ratio (log-HR) for cardiovascular

mortality (A, E), myocardial infarction (B, F), stroke (C, G), and composite renal outcome (D,

H).

The size of each trial's circle is inversely proportional to the variance of hazard ratio.

Table 1. Study characteristics.

Study name	ELIXA	LEADER	SUSTAIN-6	EXSCEL	HARMONY	REWIND	PIONEER 6	AMPLITUDE-O
Published year	2015	2016	2016	2017	2018	2019	2019	2021
Sample size	6,068	9,340	3,297	14,752	9,463	9,901	3,183	4,076
GLP-1RAs	Lixisenatide 20 µg/day	Liraglutide 1.8 mg/day	Semaglutide 0.5 or 1 mg/week	Exenatide 2 mg/week	Albiglutide 30 or 50 mg/week	Dulaglutide 1.5 mg/week	Oral semaglutide 14 mg/day	Efpeglenatide 4 or 6 mg/week
Follow-up period (median years)	2.1	3.8	2.1	3.2	1.5	5.4	1.3	1.8
Age	59.9 ± 9.7	64.2 ± 7.2	64.6 ± 7	61.9 ± 9.4	64.1 ± 8.7	66.2 ± 6.5	66.0 ± 7.0	64.5 ± 8.2
Sex (%female)	1,861 (31%)	3,337 (36%)	1,295 (39%)	5,603 (38%)	2,894 (31%)	4,589 (46%)	1,007 (32%)	1,344 (33%)
Body mass index (kg/m^2)	30.1 ± 5.6	32.5 ± 6.3	32.8 ± 6.2	32.7 ± 6.4	32.3 ± 5.9	32.3 ± 5.7	32.3 ± 6.5	32.7± 6.2
White ethnicity	4,576 (75%)	7,238 (77%)	2,736 (83%)	11,175 (76%)	6,583 (70%)	7,498 (76%)	2,300 (72%)	3,534 (87%)
duration of diabetes (years)	9.2 ± 8.2	12.8 ± 8.0	13.9 ± 8.1	13.1 ± 8.3	14.1 ± 8.7	10.5 ± 7.3	14.9 ± 8.5	15.4 ± 8.8
HbA1c (%)	7.7 ± 1.3	8.7 ± 1.6	8.7 ± 1.5	8.1 ± 1.0	8.7 ± 1.5	7.3 ± 1.1	8.2 ± 1.6	8.9 ± 1.5
eGFR (mL/min/1.73 m^2)	78 ± 21	80 (NA)	80 (61–92)	77 (61–92)	79 ± 25	75 ± 24	74 ± 21	72.4 ± 9.7
Previous cardiovascular disease	6,068 (100%)	7,598 (81.3%)	2,735 (83%)	1,0782 (73%)	9,463 (100%)	3,114 (31%)	2,695 (85%)	3,650 (90%)
Previous heart failure	1,358 (22%)	1,667 (18%)	777 (24%)	2,389 (16%)	1,922 (20%)	853 (9%)	388 (12%)	737 (18%)
Other treatments								
Insulin	2,734 (39%)	4,159 (45%)	1,913 (58%)	6,368 (46%)	5,597 (59%)	2,363 (24%)	1,930 (61%)	2,560 (63%)
Metformin	4,021 (66%)	7,136 (76%)	2,414 (73%)	1,1295 (77%)	6,968 (74%)	8,037 (81%)	2,463 (77%)	2,985 (72%)
Sulfonylurea	2,004 (33%)	4,721 (51%)	1,410 (43%)	5,401 (37%)	2,725 (29%)	4,552 (46%)	1,027 (77%)	1,036 (25%)
Thiazolidinedione	95 (2%)	573 (6%)	76 (2%)	579 (4%)	194 (2%)	168 (2%)	118 (4%)	–
DPP4 inhibitor	–	6 (<1%)	5 (<1%)	2,203 (15%)	1,437 (15%)	564 (6%)	2 (<1%)	
SGLT2 inhibitor	–	–	5 (<1%)	77 (1%)	575 (6%)	620 (6%)	305 (10%)	

Continuous variables are presented as mean ± standard deviation (except for EXSCEL), and categorical

variables are presented as number (%). Continuous data of EXSCEL are presented as median (Interquartile

range, IQR).

†eGFR data of SUSTAIN-6, EXSCEL, and REWIND are expressed as median (IQR). The standard deviation

of eGFR in LEADER was not available (NA).

GLP-1RAs = glucagon-like peptide-1, HbA1c = glycated hemoglobin, eGFR = estimated glomerular filtration

rate, DPP4 = dipeptidyl-peptidase 4, SGLT2 = sodium-glucose transport protein 2.

Figure 1.

Figure 2.

Figure 3.

(A) Primary composite MACE outcome and HbA1c reduction

(B) Primary composite MACE outcome and body weight reduction

Figure 4.